# US 9,433,638 B1 · Polymeric prodrug

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,433,638 B1
- Document ID: US9433638B1
- Status: Granted
- Kind: B1
- Application number: 14/505,381
- Filed: 2014-10-02
- Granted: 2016-09-06
- Earliest claimed: 2013-10-02
- Assignees: University of Kentucky Research Foundation
- Applicants: University of Kentucky Research Foundation
- Inventors: David Puleo; Thomas Dziubla; Theodora Asafo-Adjei
- Web page: https://patentgrep.com/patent/US9433638B1

## CPC

- A61K 31/765: Polymers containing oxygen
- A61K 31/366: having six-membered rings, e.g. delta-lactones
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The presently-disclosed subject matter includes compounds that comprise an initiator and an active agent that is covalently bonded to the initiator through a ring-opening polymerization process, an atom-transfer radical polymerization process, a Michael addition reaction, or a ring-opening metathesis polymerization process. In some embodiments the active agent includes simvastatin. The presently-disclosed subject matter also includes methods for making the compositions and methods for using the compositions to treat tissue wounds.

## Claims

### Claim 1

The compound having the formula:
wherein:
n is about 1 to about 44; and
m is about 1 to about 258.

### Claim 2 (depends on 1)

The compound of claim 1, further comprising a targeting agent.

### Claim 3 (depends on 1)

The compound of claim 1, wherein the compound includes a linear or branched structure with a molecular weight of about 500 Da to about 80 kDa.

### Claim 4 (depends on 1)

The compound of claim 1, wherein a molar ratio of the initiator to the active agent is about 1:1 to about 1:100.

### Claim 5 (depends on 1)

A method for making the compound of claim 1, comprising:
providing methoxypoly(ethylene glycol);
mixing imvastatin with the methoxypoly(ethylene glycol) to form a mixture;
adding a catalyst to the mixture; and
reacting the mixture via a ring-opening polymerization process to form the compound of claim 1.

### Claim 6 (depends on 5)

The method of claim 5, wherein a molar ratio of the methoxypoly(ethylene glycol) to simvastatin is about 1:1 to about 1:100.

### Claim 7 (depends on 5)

The method of claim 5, wherein the catalyst is selected from a metallic catalyst, an enzymatic catalyst, an organic catalyst, and combinations thereof.

### Claim 8 (depends on 1)

A method for treating a wound in a subject, comprising:
administering the composition of claim 1 to the wound.

### Claim 9 (depends on 8)

The method of claim 8, wherein the step of administering a composition includes contacting the wound with the composition.

### Claim 10 (depends on 8)

The method of claim 8, wherein the wound is a bone wound, a skin wound, or a combination thereof.